The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback